S. 1040 is a bill titled the "Drug Competition Enhancement Act" that aims to modify the Federal Trade Commission Act to prohibit a practice known as "product hopping." Product hopping is when a drug manufacturer makes minor changes to a drug to extend its market exclusivity...
Simple Explanation
S. 1040 is a rule that tries to stop medicine makers from making tiny changes to their drugs just to keep other companies from making cheaper versions. It lets a special group check if this is happening and make sure everyone plays fair.